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Abstract
N-acetylcysteine (NAC) has been suggested to prevent
radiocontrast-induced nephropathy (RCIN) in patients
with a reduced renal function. However, clinical studies
have not been demonstrating this effect consistently.
Also, reviews and meta-analyses dealing with the ques-
tion of prevention of RCIN by NAC have been controver-
sial. Nearly all investigators used serum creatinine as
surrogate end point of their trials, and changes in serum
creatinine concentrations are thought to reflect the ex-
tent of renal injury as primary outcome. In a recent study,
an effect of NAC on creatinine values and estimated glo-
merular filtration rate without any effect on cystatin C
levels has been shown in volunteers with a normal renal
function. Therefore, before renal protective effects of
NAC in RCIN are proposed, any direct effects of NAC on
creatinine, urea, and estimated glomerular filtration rate
should be addressed. In future trials, the glomerular fil-
tration rate should preferentially be measured directly,
or at least additional markers of the renal function (e.g.,
serum cystatin C) have to be assessed. Furthermore,
additional ‘hard’ end points, i.e., hospital morbidity, mor-
tality, or dialysis dependency, should be considered in
the design of future studies of RCIN.
Copyright © 2004 S. Karger AG, Basel
Introduction
Radiocontrast-induced nephropathy (RCIN) is de-
fined as a sudden decline in renal function occurring after
exposure to intravenous radiographic contrast agents that
is not attributable to other causes. Typically, the serum
creatinine level begins to increase 24–72 h after adminis-
tration of contrast medium, peaks at 3–5 days, and
requires further 3–5 days to return to baseline. In most
studies, an acute radiocontrast-agent-induced reduction
in the renal function was defined as an increase in the
serum creatinine concentration of at least 0.5 mg/dl with-
in 48 h after the administration of contrast agents.
Although several approaches have been explored to
prevent renal contrast damage, RCIN continues to be a
serious complication in patients with preexisting renal
Presented at NephroPharmacology 7 meeting, October 10, 2003,
Ulm, Germany.
162 Kidney Blood Press Res 2004;27:161–166 Hoffmann/Banas/Fischereder/Krämer
insufficiency. Effective regimens are still lacking, as the
pathogenesis of radiocontrast-induced renal dysfunction
is only partially understood.
Presently, hydration of the patient [1–3] and the use of
small amounts of low-osmolar, nonionic contrast agents
[4] are recommended. RCIN may be less likely to develop
in high-risk patients, when iso-osmolar contrast medium
is used rather than low-osmolar contrast medium [5];
however, further studies in support of this assumption are
needed. Evidence from clinical trials did not sufficiently
prove a beneficial effect of hemodialysis/hemofiltration
or theophylline, aminophylline, prostaglandins, diuretics,
dopamine, calcium channel blockers, atrial natriuretic
peptides, endothelin receptor blockers, or mannitol to rec-
ommend the general use of one of these therapies or com-
pounds [6–8].
The administration of N-acetylcysteine (NAC) seems
to be an additional option to avoid renal injury, even if
there are conflicting data about the additive protective
properties of NAC when used in conjunction with hydra-
tion [9–19]. Interestingly, the advantage of NAC in most
studies was based on a decrease in the serum creatinine
concentration in patients exposed to contrast agents plus
NAC, while often an unchanged serum creatinine concen-
tration was observed after radiocontrast exposure in pa-
tients without NAC. In a recent study [20], we have shown
that NAC led to a decrease in serum creatinine, while the
serum cystatin C concentration did not change in volun-
teers with a normal renal function.
Thus, in the present review, we will first discuss the
available evidence that NAC is able to prevent RCIN and
secondly question whether the sole measurement of se-
rum creatinine suffices as a reliable marker of the renal
function in this setting.
N-Acetylcysteine
NAC is a thiol-containing compound which stimulates
the intracellular synthesis of glutathione and enhances the
glutathione S-transferase activity [21, 22]. NAC is sup-
posed to have antioxidant properties because it sup-
presses plasma and tissue angiotensin-converting enzyme
activities [23], attenuates cytotoxic properties of ad-
vanced glycation end products [24], and decreases homo-
cysteine plasma levels [25]. NAC is demonstrated to act as
an antioxidant only in oxidative stress conditions [26].
Some reports have shown that it can inhibit nuclear factor
kappa B activation in renal mesangial and epithelial cells
[27, 28].
In animal studies, nephroprotective properties of NAC
have been demonstrated in ciclosporin-induced nephro-
toxicity as well as in ischemia/reperfusion injury [29, 30].
In contrast, no benefits of NAC administration were
found in a model of renal interstitial inflammation [31].
Moreover, at doses of 1.2 g daily, NAC may even exert
pro-oxidative properties in subjects with normal intracel-
lular glutathione levels [32].
By scavenging free radicals produced after contrast
media administration, renal toxicity might be prevented
by NAC [33]. The findings of Heyman et al. [34] in rats
suggest that NAC-related protective properties during the
evolution of acute renal failure may be mediated in part
by dilation of the constricted renal vasculature. Previous
studies already have described vasodilatory properties of
NAC [34, 35].
NAC and RCIN
Although the concept of prevention of RCIN by NAC
is favored by its simplicity and low cost, the role of NAC
for the prophylaxis of RCIN has not been established
definitively. To date, unfortunately only three trials [11,
14, 15] described the effects of NAC not only on serum
creatinine but also on clinical end points. Kay et al. [11]
investigated the effect of NAC on the length of hospital
stay as a secondary end point and found a significant
reduction of 12 h in patients given NAC. In another pro-
spective, randomized, double-blind, and placebo-con-
trolled study designed to evaluate the efficacy and safety
of NAC in the prevention of RCIN in patients undergoing
coronary angiography [14], there was no difference in
length of stay, hospital charges, or serum creatinine
changes between the NAC-treated and the control group.
Goldenberg et al. [15] reported similar findings in pa-
tients with chronic renal insufficiency undergoing cardiac
catheterization. The incidence of in-hospital adverse clin-
ical events and the length of hospital stay did not differ
between the NAC-treated and the control groups, and
there were no differences in creatinine levels between the
treatment groups.
In all other studies, due to the rare occurrence of severe
clinical adverse events after radiocontrast administration,
only surrogate markers of a reduced glomerular filtration
rate (GFR), such as creatinine or urea, have been used as
primary outcome, and renal injury has been accordingly
extrapolated from changes in serum chemistry. This con-
stitutes a major limitation of such studies. When review-
ing the published studies to date, one has to keep in mind
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that publication bias may well be present and that the
comparability between trials is limited due to differences
in baseline characteristics of the patients and in major
study design details, particularly the severity of chronic
renal insufficiency before the procedure and the amount
of radiocontrast media.
Several meta-analyses of the presently available data
concerning the role of NAC in the prevention of RCIN
have been published during the last months. Birck et al.
[19] in their meta-analysis studied seven randomized con-
trolled trials comparing orally given NAC and hydration
with hydration alone for preventing RCIN in a total of
805 patients with chronic renal insufficiency. The com-
mon end point of all these studies was a change in the
serum creatinine concentration. A rise in serum creati-
nine 10.5 mg/dl was considered to indicate RCIN. Four
studies [9–11, 36] showed a statistically significant reduc-
tion of the relative risk for the development of RCIN in
patients given NAC, whereas the remaining three showed
no significant benefit of preprocedural NAC [17, 18, 37].
By combining the effect sizes of these seven trials by a
random-effects model, a significant relative risk reduction
of 56% was seen in patients given NAC. Alonso et al. [38]
and Findlay and Dwomoa [39] described nearly similar
findings when performing meta-analyses of both seven
blinded and unblinded randomized controlled trials, but
in both analyses, there was a significant heterogeneity of
the effect of therapy. Another recent meta-analysis per-
formed by Pannu et al. [40] found only a borderline statis-
tical significance of the efficacy of NAC for preventing
RCIN. However, in this analysis, the effect of NAC was
not statistically significant in several prespecified sub-
group analyses, and the results were not robust to the
addition of hypothetical new or unidentified randomized
trials. In a further recently published meta-analysis of
eleven studies [41], no benefit of NAC in reducing the risk
of RCIN in patients with baseline renal dysfunction was
found.
In a new experimental study performed by Emch and
Haller [42], a method for preventing renal tubular vacuo-
lization by administration of NAC prior to contrast me-
dium administration was tested in rats. The occurrence of
renal tubular vacuolization in the NAC-treated groups
was similar to that in control groups.
In contrast to all other studies assessing the effects of
orally administered NAC, a recent study [43] compared
intravenous NAC and hydration given immediately be-
fore coronary angiography/intervention with hydration
alone for the prevention of RCIN. In the NAC-treated
group, the mean serum creatinine concentration de-
creased significantly from 1.85 to 1.77 mg/dl 48 h after
contrast agent administration. In the group without NAC,
the serum creatinine level increased slightly but not signif-
icantly. RCIN, defined in this study as an increase in the
serum creatinine concentration by 25% occurred in 2 of
the 41 patients in the NAC-treated group and in 8 of 39
patients in the group not receiving NAC (p = 0.045). After
intravenous injection of NAC, however, 14.5% of the
patients suffered flushing, itching, or rash.
Besides the question of the efficacy of NAC for RCIN
prevention, it has to be asked whether the serum creati-
nine concentration is a reliable surrogate marker for the
renal function at all. It is well known that the serum con-
centration of creatinine is determined not just by the
GFR. Alterations in renal handling, i.e., tubular secretion
and metabolism of creatinine, and methodological inter-
ference in its measurement may influence the serum con-
centration of creatinine. Due to dietary creatinine intake,
tubular secretion of creatinine, and variations in the
patient’s muscle mass, the use of serum creatinine may
inaccurately estimate the GFR.
Rickli et al. [44] recently compared serum cystatin C
and serum creatinine to examine their kinetics after appli-
cation of radiocontrast media in patients with a normal to
decreased GFR. In this study, cystatin C achieved a maxi-
mum increase within 24 h after radiocontrast application,
whereas serum creatinine started to increase at that time
and continued to increase at 48 h. Cystatin C is suggested
to be a potential early marker of nephrotoxicity.
In a recent prospective study [20], we have studied the
potential effects of NAC on serum creatinine, indepen-
dent of alterations in the GFR. For this purpose, volun-
teers with a normal renal function who did not receive
radiocontrast media were enrolled. NAC was given orally
at a dose of 600 mg every 12 h for a total of four doses.
The serum levels of creatinine, urea, albumin, and cysta-
tin C were determined before administration of NAC and
4 and 48 h after the last intake. Serum creatinine was mea-
sured both enzymatically and by the Jaffé method. The
GFR was estimated (eGFR) on the basis of serum creati-
nine, urea, and albumin concentrations and weight, age,
and sex, using the equation developed by Levey et al. [45].
There was a significant decrease of the mean serum creati-
nine concentration (p ! 0.05) and a significant increase of
the eGFR (p ! 0.02) 4 h after the last administration of
NAC, whereas the cystatin C concentration did not
change significantly (fig. 1). The latter observation is not
quite unexpected, as direct effects of NAC on the human
renal function have not been reported yet. Taken togeth-
er, two explanations for our findings are possible:
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Fig. 1. Surrogate markers of the renal function. Mean serum creati-
nine (a), eGFR (b), and cystatin C (c) before (baseline) and 4 h after
the last intake of NAC. There were a significant decrease of the mean
serum creatinine concentration (* p ! 0.05) and a significant increase
of the eGFR (** p ! 0.02) 4 h after the last administration of NAC,
whereas the cystatin C concentration did not change significantly
[20].
First, NAC truly improves the GFR, but cystatin C
fails to detect such an improvement. This appears unlike-
ly, since several studies comparing cystatin C and creati-
nine with the GFR employing the 51Cr-EDTA clearance,
the gold standard to measure the GFR, documented that
cystatin C determination is superior to creatinine mea-
surement [46–49]. Furthermore, contrary to the serum
creatinine concentration, the serum cystatin C level is
independent of age, sex, and muscle mass.
Second, NAC does not alter the GFR, but causes a
decrease in the serum creatinine concentration through
another mechanism. A number of reasons favor this
assumption. Creatinine is predominantly but not exclu-
sively eliminated by glomerular filtration. Especially in
patients with an impaired renal function, the extent of
tubular secretion may contribute significantly to the total
creatinine excretion. Furthermore, the creatinine metabo-
lism is affected by NAC either through direct activation of
creatinine kinase or through reversal of inhibition by free
radicals [50].
Although these data were obtained in healthy adults, it
is likely that the underlying physiological mechanisms are
the same in individuals with renal disease. In contrast, the
effects of NAC on renal tubular creatinine secretion or
muscle metabolism may be even more prominent in such
patients. However, to prove the same effect in patients
with an impaired renal function, further studies using a
similar protocol without administration of contrast agents
have to be done. Nevertheless, the data obtained in our
study clearly cast some doubt on the present practice to
administer NAC for protection from RCIN.
Conclusions
Efficacious and safe prevention of RCIN is expected to
decrease morbidity, including the need for dialysis, and
mortality during hospitalization and thus should reduce
health care costs. So far, only hydration and the use of low-
osmolar contrast media proved to be beneficial. When the
role of NAC in human RCIN is studied, special attention
must be given to the end point used to determine presence
or absence of renal injury. The presently available data
from human studies as well as the meta-analyses represent
a special dilemma, as they show conflicting results, even for
the most common surrogate end point serum creatinine. In
a recent study [20], we have shown that NAC leads to a
decrease of serum creatinine, but that another surrogate
marker of renal function, serum cystatin C, does not
change after NAC administration.
Therefore, it is suggested to assess hard clinical end
points rather than solely changes in serum creatinine in
future studies. If surrogate parameters of renal function
are used to prove the protective effect of NAC, the study
designs should preferably include direct GFR measure-
ments or include at least another surrogate marker of the
renal function, e.g., cystatin C.
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